Do analysts rate FEED or NMTC?

NeuroOne Medical Technologies has a consensus price target of $7.33, indicating a potential upside of 352.67%. Given NeuroOne Medical Technologies' stronger consensus rating and higher probable upside, analysts clearly believe NeuroOne Medical Technologies is more favorable than Nanovibronix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nanovibronix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NeuroOne Medical Technologies 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Do analysts prefer TMDIF or FEED?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Titan Medical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Nanovibronix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate ICU or FEED?

SeaStar Medical currently has a consensus price target of $8.00, indicating a potential upside of 168.46%. Given SeaStar Medical's stronger consensus rating and higher possible upside, equities analysts clearly believe SeaStar Medical is more favorable than Nanovibronix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SeaStar Medical 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Nanovibronix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer FEED or IRIX?

IRIDEX has a consensus target price of $3.00, indicating a potential upside of 328.57%. Given IRIDEX's stronger consensus rating and higher probable upside, analysts clearly believe IRIDEX is more favorable than Nanovibronix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nanovibronix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 IRIDEX 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation & earnings, FEED or IRIX?

IRIDEX has higher revenue and earnings than Nanovibronix. IRIDEX is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nanovibronix $2.55M 1.45 -$18.18M -$9.77 N/A IRIDEX $52.67M 0.23 -$4.44M -$0.20 N/A

Is FEED or IRIX more profitable?

IRIDEX has a net margin of -6.88% compared to Nanovibronix's net margin of -1,093.61%. IRIDEX's return on equity of 0.00% beat Nanovibronix's return on equity. Company Net Margins Return on Equity Return on Assets Nanovibronix -1,093.61% -60.73% -48.48% IRIDEX -6.88% N/A -12.55%

Do analysts recommend HSCS or FEED?

HeartSciences currently has a consensus target price of $8.00, suggesting a potential upside of 114.48%. Given HeartSciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe HeartSciences is more favorable than Nanovibronix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HeartSciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Nanovibronix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer HSCS or FEED?

In the previous week, Nanovibronix had 1 more articles in the media than HeartSciences. MarketBeat recorded 2 mentions for Nanovibronix and 1 mentions for HeartSciences. HeartSciences' average media sentiment score of 0.00 equaled Nanovibronix'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HeartSciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nanovibronix 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Nanovibronix (FEED) Competitors

$4.03 +0.20 (+5.22%)

As of 09/4/2026 04:00 PM Eastern

Compare

FEED vs. NMTC, TMDIF, ICU, IRIX, and HSCS

Should you buy Nanovibronix stock or one of its competitors? Nanovibronix's main competitors and comparable companies include NeuroOne Medical Technologies (NMTC), Titan Medical (TMDIF), SeaStar Medical (ICU), IRIDEX (IRIX), and HeartSciences (HSCS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Nanovibronix compare to NeuroOne Medical Technologies?

Nanovibronix (NASDAQ:FEED) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings.

NeuroOne Medical Technologies has a net margin of -71.50% compared to Nanovibronix's net margin of -1,093.61%. Nanovibronix's return on equity of -60.73% beat NeuroOne Medical Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanovibronix	-1,093.61%	-60.73%	-48.48%
NeuroOne Medical Technologies	-71.50%	-128.12%	-86.34%

In the previous week, Nanovibronix had 2 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 2 mentions for Nanovibronix and 0 mentions for NeuroOne Medical Technologies. Nanovibronix's average media sentiment score of 0.00 equaled NeuroOne Medical Technologies'average media sentiment score.

Company	Overall Sentiment
Nanovibronix	Neutral
NeuroOne Medical Technologies	Neutral

16.4% of Nanovibronix shares are held by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are held by institutional investors. 12.2% of Nanovibronix shares are held by insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

NeuroOne Medical Technologies has a consensus price target of $7.33, indicating a potential upside of 352.67%. Given NeuroOne Medical Technologies' stronger consensus rating and higher probable upside, analysts clearly believe NeuroOne Medical Technologies is more favorable than Nanovibronix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Nanovibronix has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market. Comparatively, NeuroOne Medical Technologies has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market.

NeuroOne Medical Technologies has higher revenue and earnings than Nanovibronix. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanovibronix	$2.55M	1.45	-$18.18M	-$9.77	N/A
NeuroOne Medical Technologies	$12.10M	1.22	-$3.61M	-$0.95	N/A

Summary

Nanovibronix beats NeuroOne Medical Technologies on 8 of the 15 factors compared between the two stocks.

How does Nanovibronix compare to Titan Medical?

Titan Medical (NASDAQ:TMDIF) and Nanovibronix (NASDAQ:FEED) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

Titan Medical has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market. Comparatively, Nanovibronix has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market.

0.0% of Titan Medical shares are held by institutional investors. Comparatively, 16.4% of Nanovibronix shares are held by institutional investors. 0.0% of Titan Medical shares are held by company insiders. Comparatively, 12.2% of Nanovibronix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Titan Medical has a net margin of 0.00% compared to Nanovibronix's net margin of -1,093.61%. Nanovibronix's return on equity of -60.73% beat Titan Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Titan Medical	N/A	-82.31%	-51.47%
Nanovibronix	-1,093.61%	-60.73%	-48.48%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Titan Medical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Nanovibronix had 2 more articles in the media than Titan Medical. MarketBeat recorded 2 mentions for Nanovibronix and 0 mentions for Titan Medical. Titan Medical's average media sentiment score of 0.00 equaled Nanovibronix'saverage media sentiment score.

Company	Overall Sentiment
Titan Medical	Neutral
Nanovibronix	Neutral

Titan Medical has higher revenue and earnings than Nanovibronix. Nanovibronix is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Titan Medical	$17.63M	0.83	$6.95M	$0.05	2.58
Nanovibronix	$2.55M	1.45	-$18.18M	-$9.77	N/A

Summary

Nanovibronix beats Titan Medical on 8 of the 13 factors compared between the two stocks.

How does Nanovibronix compare to SeaStar Medical?

SeaStar Medical (NASDAQ:ICU) and Nanovibronix (NASDAQ:FEED) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

SeaStar Medical has higher earnings, but lower revenue than Nanovibronix. SeaStar Medical is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SeaStar Medical	$1.23M	10.68	-$12.15M	-$3.91	N/A
Nanovibronix	$2.55M	1.45	-$18.18M	-$9.77	N/A

SeaStar Medical currently has a consensus price target of $8.00, indicating a potential upside of 168.46%. Given SeaStar Medical's stronger consensus rating and higher possible upside, equities analysts clearly believe SeaStar Medical is more favorable than Nanovibronix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SeaStar Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

SeaStar Medical has a beta of -1.05, suggesting that its stock price is 205% less volatile than the broader market. Comparatively, Nanovibronix has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market.

1.7% of SeaStar Medical shares are owned by institutional investors. Comparatively, 16.4% of Nanovibronix shares are owned by institutional investors. 0.7% of SeaStar Medical shares are owned by insiders. Comparatively, 12.2% of Nanovibronix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

SeaStar Medical has a net margin of -795.51% compared to Nanovibronix's net margin of -1,093.61%. Nanovibronix's return on equity of -60.73% beat SeaStar Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SeaStar Medical	-795.51%	-162.75%	-109.89%
Nanovibronix	-1,093.61%	-60.73%	-48.48%

In the previous week, Nanovibronix had 2 more articles in the media than SeaStar Medical. MarketBeat recorded 2 mentions for Nanovibronix and 0 mentions for SeaStar Medical. SeaStar Medical's average media sentiment score of 0.00 equaled Nanovibronix'saverage media sentiment score.

Company	Overall Sentiment
SeaStar Medical	Neutral
Nanovibronix	Neutral

Summary

Nanovibronix beats SeaStar Medical on 8 of the 15 factors compared between the two stocks.

How does Nanovibronix compare to IRIDEX?

Nanovibronix (NASDAQ:FEED) and IRIDEX (NASDAQ:IRIX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

Nanovibronix has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market. Comparatively, IRIDEX has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market.

16.4% of Nanovibronix shares are owned by institutional investors. Comparatively, 20.1% of IRIDEX shares are owned by institutional investors. 12.2% of Nanovibronix shares are owned by insiders. Comparatively, 8.6% of IRIDEX shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

IRIDEX has higher revenue and earnings than Nanovibronix. IRIDEX is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanovibronix	$2.55M	1.45	-$18.18M	-$9.77	N/A
IRIDEX	$52.67M	0.23	-$4.44M	-$0.20	N/A

IRIDEX has a consensus target price of $3.00, indicating a potential upside of 328.57%. Given IRIDEX's stronger consensus rating and higher probable upside, analysts clearly believe IRIDEX is more favorable than Nanovibronix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
IRIDEX	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

IRIDEX has a net margin of -6.88% compared to Nanovibronix's net margin of -1,093.61%. IRIDEX's return on equity of 0.00% beat Nanovibronix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanovibronix	-1,093.61%	-60.73%	-48.48%
IRIDEX	-6.88%	N/A	-12.55%

In the previous week, Nanovibronix had 2 more articles in the media than IRIDEX. MarketBeat recorded 2 mentions for Nanovibronix and 0 mentions for IRIDEX. Nanovibronix's average media sentiment score of 0.00 equaled IRIDEX'saverage media sentiment score.

Company	Overall Sentiment
Nanovibronix	Neutral
IRIDEX	Neutral

Summary

IRIDEX beats Nanovibronix on 10 of the 15 factors compared between the two stocks.

How does Nanovibronix compare to HeartSciences?

HeartSciences (NASDAQ:HSCS) and Nanovibronix (NASDAQ:FEED) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

HeartSciences has a net margin of 0.00% compared to Nanovibronix's net margin of -1,093.61%. Nanovibronix's return on equity of -60.73% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartSciences	N/A	-358.60%	-144.82%
Nanovibronix	-1,093.61%	-60.73%	-48.48%

17.2% of HeartSciences shares are owned by institutional investors. Comparatively, 16.4% of Nanovibronix shares are owned by institutional investors. 4.9% of HeartSciences shares are owned by company insiders. Comparatively, 12.2% of Nanovibronix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

HeartSciences has higher earnings, but lower revenue than Nanovibronix. HeartSciences is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartSciences	N/A	N/A	-$9.14M	-$3.94	N/A
Nanovibronix	$2.55M	1.45	-$18.18M	-$9.77	N/A

HeartSciences has a beta of 1.85, indicating that its share price is 85% more volatile than the broader market. Comparatively, Nanovibronix has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market.

HeartSciences currently has a consensus target price of $8.00, suggesting a potential upside of 114.48%. Given HeartSciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe HeartSciences is more favorable than Nanovibronix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Nanovibronix had 1 more articles in the media than HeartSciences. MarketBeat recorded 2 mentions for Nanovibronix and 1 mentions for HeartSciences. HeartSciences' average media sentiment score of 0.00 equaled Nanovibronix'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HeartSciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nanovibronix	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

HeartSciences beats Nanovibronix on 8 of the 14 factors compared between the two stocks.

Get Nanovibronix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FEED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FEED vs. The Competition

Export

Metric	Nanovibronix	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.72M	$5.76B	$7.25B	$12.92B
Dividend Yield	N/A	1.76%	2.53%	9.14%
P/E Ratio	-0.41	25.82	273.54	25.43
Price / Sales	1.45	73.52	630.97	107.01
Price / Cash	N/A	32.98	77.08	52.44
Price / Book	0.12	6.06	12.85	6.17
Net Income	-$18.18M	$150.92M	$3.49B	$350.08M
7 Day Performance	-2.52%	-1.22%	1.04%	-0.14%
1 Month Performance	-14.98%	2.18%	5.39%	0.94%
1 Year Performance	N/A	9.95%	24.18%	14.02%

Nanovibronix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FEED Nanovibronix	0.4905 of 5 stars	$4.03 +5.2%	N/A	N/A	$3.72M	$2.55M	N/A	20
NMTC NeuroOne Medical Technologies	2.0208 of 5 stars	$1.67 +3.7%	$7.33 +339.1%	-65.9%	$14.66M	$12.10M	N/A	20
TMDIF Titan Medical	N/A	$0.12 -3.8%	N/A	-60.7%	$13.26M	$17.63M	N/A	50	Gap Up
ICU SeaStar Medical	2.6613 of 5 stars	$2.88 -3.7%	$8.00 +177.8%	-62.5%	$13.18M	$1.71M	N/A	2	Gap Down
IRIX IRIDEX	1.6212 of 5 stars	$0.72 -1.3%	$3.00 +316.7%	-50.0%	$12.82M	$52.67M	N/A	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FEED) was last updated on 9/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nanovibronix (FEED) Competitors

FEED vs. NMTC, TMDIF, ICU, IRIX, and HSCS

How does Nanovibronix compare to NeuroOne Medical Technologies?

Summary

How does Nanovibronix compare to Titan Medical?

Summary

How does Nanovibronix compare to SeaStar Medical?

Summary

How does Nanovibronix compare to IRIDEX?

Summary

How does Nanovibronix compare to HeartSciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FEED vs. The Competition

Nanovibronix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nanovibronix (FEED) Competitors

FEED vs. NMTC, TMDIF, ICU, IRIX, and HSCS

How does Nanovibronix compare to NeuroOne Medical Technologies?

Is FEED or NMTC more profitable?

Does the media refer more to FEED or NMTC?

Do institutionals & insiders believe in FEED or NMTC?

Do analysts rate FEED or NMTC?

Which has more volatility & risk, FEED or NMTC?

Which has better earnings & valuation, FEED or NMTC?

Summary

How does Nanovibronix compare to Titan Medical?

Which has more risk & volatility, TMDIF or FEED?

Do insiders and institutionals hold more shares of TMDIF or FEED?

Is TMDIF or FEED more profitable?

Do analysts prefer TMDIF or FEED?

Does the media prefer TMDIF or FEED?

Which has stronger earnings and valuation, TMDIF or FEED?

Summary

How does Nanovibronix compare to SeaStar Medical?

Which has higher earnings and valuation, ICU or FEED?

Do analysts rate ICU or FEED?

Which has more risk & volatility, ICU or FEED?

Do institutionals & insiders hold more shares of ICU or FEED?

Is ICU or FEED more profitable?

Does the media favor ICU or FEED?

Summary

How does Nanovibronix compare to IRIDEX?

Which has more volatility and risk, FEED or IRIX?

Do insiders & institutionals believe in FEED or IRIX?

Which has stronger valuation & earnings, FEED or IRIX?

Do analysts prefer FEED or IRIX?

Is FEED or IRIX more profitable?

Does the media refer more to FEED or IRIX?

Summary

How does Nanovibronix compare to HeartSciences?

Is HSCS or FEED more profitable?

Do insiders & institutionals hold more shares of HSCS or FEED?

Which has stronger earnings & valuation, HSCS or FEED?

Which has more risk & volatility, HSCS or FEED?

Do analysts recommend HSCS or FEED?

Does the media prefer HSCS or FEED?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FEED vs. The Competition

Nanovibronix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools